Group 1 - The North Exchange will officially launch the North Specialized and Innovative Index on June 30, 2025, which will provide multi-dimensional investment targets and performance benchmarks [1][9] - The index will consist of the 50 largest "little giant" companies listed on the North Exchange, reflecting the overall performance of specialized and innovative companies [1][9] - As of June 6, 2025, there are 146 national-level specialized and innovative "little giant" companies listed on the North Exchange, accounting for 54.89% of the total [1][14][17] Group 2 - In 2024, the average revenue of national-level specialized and innovative companies on the North Exchange was 613 million yuan, while non-national-level companies had an average revenue of 768 million yuan, with year-on-year changes of -6.88% and +2.40% respectively [1][15] - The average net profit attributable to shareholders for national-level specialized and innovative companies was 47.83 million yuan, compared to 35.16 million yuan for non-national-level companies, with year-on-year changes of -20.72% and -24.34% respectively [1][15] - The gross profit margin for national-level specialized and innovative companies was 25.11%, while for non-national-level companies it was 21.83% [21][24] Group 3 - The North Exchange's A-shares had an average daily trading volume of 24.83 billion yuan, a decrease of 2.38% from the previous week, with a turnover rate of 6.18% [2][30] - The North 50 Index closed at 1427.06 points, with a week-on-week increase of 1.30% and a PE ratio of 74.42X [2][31][35] - The overall PE ratio for North Exchange A-shares increased to 50.21X, with 144 companies having a PE ratio exceeding 45X, accounting for 54.55% [2][33][38] Group 4 - The five major industries on the North Exchange, including high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, have TTM PE ratios of 40.68X, 101.69X, 42.50X, 56.05X, and 51.53X respectively [2][37][39] - The North Exchange focuses on serving innovative small and medium-sized enterprises, particularly in advanced manufacturing and modern service industries, to promote high-quality economic development [1][14]

Group 1: Investor Relations Activity - The investor relations activity was an earnings briefing held online on May 15, 2025, from 15:00 to 16:30 [3] - Key participants included the Chairman, Chief Scientific Officer, Chief Capital Officer, Chief Financial Officer, and the Board Secretary [3] Group 2: HPV Vaccine Development - The three-valent HPV vaccine was included in the priority review list by the National Medical Products Administration (NMPA) in March 2025, with the application accepted in April 2025 [4][5] - The review period for the three-valent HPV vaccine is shortened from 200 working days to 130 working days due to priority review [4] - The nine-valent HPV vaccine for female indications is currently undergoing phase III clinical trials, with the 42 and 48-month visits ongoing [6] - The nine-valent HPV vaccine for male indications is also in phase III trials, with 18 and 24-month visits currently being conducted [6][10] Group 3: Regulatory and Market Strategy - The company is actively communicating with the NMPA to ensure compliance and expedite the review process for the nine-valent HPV vaccine [8] - The nine-valent HPV vaccine (female indication) is expected to submit its Biologics License Application (BLA) soon, with the timeline being a few months behind the three-valent vaccine [7] - The company has adjusted its strategy in Indonesia from building a manufacturing base to collaborating with local partners for registration and market access [13][14] Group 4: Financial and Funding Strategies - The company plans to address funding shortages through various financing channels, including equity and debt financing, while maintaining high R&D investment [16] - A loan of up to 477 million yuan is being organized by a banking syndicate, with approval completed by the lead bank [19] - The company aims to enhance cash flow management and reduce operational costs to improve financial stability [18][20]

Core Viewpoint - 康乐卫士 is currently in a loss-making state with no products commercialized, reporting a revenue of 885,600 yuan in 2024, a decrease of 50.24% year-on-year, and a net profit of -357 million yuan, down 18.51% year-on-year [1] Group 1: Financial Performance - In 2024, 康乐卫士 reported a revenue of 885,600 yuan, a decline of 50.24% compared to the previous year [1] - The net profit attributable to the parent company was -357 million yuan, representing a year-on-year decrease of 18.51% [1] - The operating cash flow was -125 million yuan, indicating a reliance on external financing for working capital [3] Group 2: Research and Development - 康乐卫士 has a total of 9 vaccine candidates in development, including 8 recombinant protein candidates and 1 mRNA candidate [2] - Key products such as the trivalent HPV vaccine and the nine-valent HPV vaccines for both female and male indications have entered Phase III clinical trials [2] - The trivalent HPV vaccine's market approval application has been accepted by the National Medical Products Administration (NMPA) and is included in the priority review process [2] Group 3: Operational Strategy - 康乐卫士 is transitioning towards becoming a commercial pharmaceutical company and has established a production base in Kunming that meets GMP standards, with an annual production capacity of 10 million doses of the trivalent HPV vaccine and 30 million doses of the nine-valent HPV vaccine [2] - The company has introduced a systematic response plan to address the risk of insufficient working capital, which includes accelerating HPV vaccine development and commercialization, optimizing asset utilization, actively seeking financing, and enhancing internal management to reduce costs and increase efficiency [3] Group 4: Recent Developments - In the first quarter of 2024, 康乐卫士 reported a 90.51% decline in revenue, while the net profit attributable to the parent company increased by 18.12% year-on-year [4]

Group 1: Starbucks - Starbucks CEO Brian Niccol announced an increase in store staff and a reduction in automation investments, breaking the trend of relying more on technology in store operations [1] - Niccol emphasized that increasing manpower is crucial for improving customer experience, which has been a primary goal since he took office in September last year [1] - The company previously aimed for equipment to offset labor reductions, but found this assumption inaccurate based on results [1] Group 2: Kanglaoshi - Kanglaoshi reported a revenue of 88.56 million yuan for 2024, a decrease of 50.24% year-on-year, with a net loss of 357 million yuan, down 18.51% [1] - R&D expenses increased by 7.46% to 254 million yuan, with core product development progressing as planned [1] - The company is on track to complete three-phase clinical trials for its HPV vaccines in 2024 and 2025 [1] Group 3: Caocao Mobility - Caocao Mobility updated its prospectus, reporting a revenue of 14.7 billion yuan for 2024, a year-on-year growth of 37.4% [6] - The company expanded its ride-hailing operations to 136 cities, adding 85 cities since the end of 2023 [6] - The gross margin improved from 5.8% in 2023 to 8.1% in 2024, ranking second in domestic ride-hailing platforms by GTV [6] Group 4: A-share Companies - A-share companies reported a total revenue of 70.6 trillion yuan and a net profit of 5.25 trillion yuan for 2024 [4] - Nearly 60% of A-share companies saw revenue growth, and about 80% reported profitability [4] - The number of companies with net profits exceeding 100 billion yuan increased to 10, while 117 companies surpassed 10 billion yuan in revenue [4] Group 5: Samsung Electronics - Samsung Electronics reported a net profit of 8.03 trillion won for Q1, exceeding expectations of 5.58 trillion won [4] - The operating profit for the same period was 6.69 trillion won, with sales reaching 79.14 trillion won [4] - The chip business generated an operating profit of 1.1 trillion won in Q1 [4] Group 6: Intel - Intel announced a total capital investment of 90 billion dollars over four years for its wafer foundry business [4] - The company is in the risk trial production phase for its 18A process node, expected to enter mass production by the end of 2025 [4] - The next-generation 14A process node is scheduled for mass production in 2027, one year ahead of TSMC [4] Group 7: Old Pile Gold - Old Pile Gold will officially open its second store in Shanghai at the Hongqiao Henglong Plaza on May 1 [2] - The company has signed contracts to enter major commercial centers in China, with plans for additional store openings in Shanghai and Hong Kong by 2025 [2] Group 8: Ele.me - Ele.me announced a significant increase in platform subsidies, launching a promotion called "Ele.me Super 100 Billion" [3] Group 9: Investment and Financing - Huiye (Fujian) Electric Co., Ltd. completed a 30 million yuan A-round financing to develop a new generation of distribution network automation systems [7] - Chuanbai (Tianjin) Catering Management Co., Ltd. completed a 48 million yuan Pre-A financing for brand expansion and supply chain integration [8] Group 10: Meta - Meta launched a standalone AI application to compete directly with ChatGPT, utilizing its Llama AI model [9]

证券简称： 康乐卫士 证券代码： 833575 北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 北京康乐卫士生物技术股份有限公司 BEIJING HEALTH GUARD BIOTECHNOLOGY INC. 北京康乐卫士生物技术股份有限公司招股说明书 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 联席主承销商 北京市西城区车公庄大街 4 号 2 幢 1 层 A2112 室 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化 ...

北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 北京康乐卫士生物技术股份有限公司 BEIJING HEALTH GUARD BIOTECHNOLOGY INC. 北京康乐卫士生物技术股份有限公司招股说明书（注册稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 联席主承销商 北京市西城区车公庄大街 4 号 2 幢 1 层 A2112 室 证券简称： 康乐卫士 证券代码： 833575 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能 ...

证券简称： 康乐卫士 证券代码： 833575 北京康乐卫士生物技术股份有限公司 BEIJING HEALTH GUARD BIOTECHNOLOGY INC. 北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 北京康乐卫士生物技术股份有限公司招股说明书（注册稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1-1-1 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相 ...

证券简称： 康乐卫士 证券代码： 833575 北京康乐卫士生物技术股份有限公司 BEIJING HEALTH GUARD BIOTECHNOLOGY INC. 北京市北京经济技术开发区荣昌东街 7 号 A2 幢 201、202 北京康乐卫士生物技术股份有限公司招股说明书（注册稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1-1-1 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相 ...